Chapter 27: Thrombosis 1: Pathogenesis and Diagnosis

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

Today, we are plunging right into a really vital and

complex area of medicine.

We are.

Our source material is Hawk Brand's Essential Hematology, Chapter 27, and our topic is thrombosis.

Specifically, the pathogenesis and diagnosis, how blood clots form.

Exactly.

This is a deep dive into what are really the silent drivers of so much mortality and morbidity.

So our mission today is to synthesize this really dense but clinically crucial chapter.

Right.

We're focusing on how these clots or thrombi actually form, what factors, both genetic and acquired, can tilt the balance toward clotting.

And then how clinicians can diagnose these events quickly.

Yes.

The goal here is to build a really rock -solid, student -friendly understanding of both arterial and venous thrombosis.

Yeah, if you're trying to master blood disorders, understanding thrombosis is just, it's non -negotiable.

It really is.

It's the root of myocardial infarction, stroke, pulmonary embolism, the big killers.

So let's start with the absolute basics.

What exactly is a thrombus and why is that different from, you know, a normal clot you'd get from a cut?

That's the critical distinction.

A thrombus is a solid mass, a plug that's formed inside the circulating blood system.

So not in response to an external injury?

Precisely.

Normal clotting or hemostasis is a controlled, localized response to stop you from bleeding.

A thrombus is pathological.

It's coagulation gone rogue.

It's happening where it shouldn't be.

And when it shouldn't be.

This uncontrolled formation is what causes ischemia, the deprivation of oxygenated blood.

And that leads to all those devastating outcomes we just mentioned.

And when we talk about people who are predisposed to this, we use the term thrombophilia.

Correct.

Thromophilia is the umbrella term.

It covers any inherited or acquired disorder in the hemostatic mechanism that predisposes someone to thrombosis.

It's an important concept because it makes you look beyond just the acute clot.

Yes.

It forces the clinician to think about the underlying long -term risk.

And a really key clinical observation is that thrombosis risk, both in arteries and veins, is strongly correlated with age.

The older you get, the higher the risk.

Risk just goes up.

Okay, so let's unpack this with a more modern idea.

I think when most of us think about clotting, we just think of the coagulation cascade, you know, factor X, factor V.

A classical pathway, yeah.

But the sources today really highlight the, frankly, alarming role of inflammation.

This is one of the key conceptual updates in hematology.

Inflammation isn't just floating around nearby.

It's a direct accelerator.

For both arterial and venous clots.

For both.

And it does this by hitting the system from two directions at once.

It pushes the go button and takes its foot off the brake.

Okay, so how does it promote clotting?

What's it upregulating?

Inflammation causes a direct increase in procoagulant factors, things like fibrinogen.

The scaffolding for the clot.

The main structural scaffolding, and also factor VIII and Von Mollebrand factor.

These are what we call acute phase reactants.

Their levels just shoot up, making the blood more, well, more ready to clot.

And taking the foot off the brake.

How does that work?

It's equally targeted.

The source points to a fascinating detail.

Inflammation causes a drop in free protein S.

And protein S is one of the body's key natural anticoagulants.

A crucial one.

It's a cofactor for activated protein C.

The reason the free level drops is that it gets bound up by another protein,

complement C4B binding protein, which, you guessed it, is also raised during inflammation.

So it's being sequestered.

Taken out of play.

Exactly.

The body temporarily loses one of its most important built -in safety mechanisms.

Some more clotting factors, fewer inhibitors, a double whammy.

But there's another piece to this inflammation story, isn't there?

Neutrophil extracellular traps, or NETs.

Ah, yes, NETs.

This is where the immune system literally becomes part of the clot.

What are they?

So neutrophils, a type of white blood cell, can essentially eject their own DNA.

It's decondensed, mixed with proteins like histones and enzymes, and it forms this sticky mesh -like structure.

A physical trap.

Physical sticky trap.

And these NETs don't just float by.

They provide a scaffold that physically traps red blood cells, and, critically, they actively activate platelets.

Wow.

So they are a structural, active component of the thrombus itself.

In both arteries and veins.

So if you're looking for that molecular bridge between, say, sepsis or inflammatory bowel disease and a blood clot,

NETs are right in the middle of it.

That sets the stage perfectly for our first section, arterial thrombosis.

And as you said, when we talk about arterial clots, we are really talking about a mechanical problem first.

Unlike the venous system, arterial thrombi are fundamentally tied to vessel wall injury.

And the core pathology, the underlying problem, is atherosclerosis.

So let's walk through that sequence.

How do we get from a stable artery to an acute, life -threatening event?

It all starts with the rupture of an unstable atherosclerotic plaque.

That fatty deposit in the artery wall.

Right.

When that ruptures, you get immediate endothelial injury.

The smooth inner lining of the blood vessel is damaged, and everything that's normally hidden underneath is suddenly exposed to the bloodstream.

Which includes?

Subendothelial collagen,

and most critically, tissue factor.

Factor three.

Tissue factor.

The big alarm bell for the extrinsic pathway?

The biggest.

Its exposure kicks off this massive rapid formation of what we call a plateletitis.

Platelets just swarm to the site, stick to the collagen, and then aggregate into a plug.

A platelet -rich plug.

Yes.

And that plug then rapidly traps fibrin to consolidate itself into a hard thrombus, which can block the artery right there.

You know, what I find striking is the dual role of platelets here.

They're the first responders, but they're also part of the long -term problem.

They absolutely are.

They are not passive victims in this story.

Platelets release all sorts of growth factors, but the most important one here is platelet -derived growth factor, or PDGF.

And what does PDGF do?

It actively encourages smooth muscle cells and fibroblasts to migrate and multiply in the artery wall.

Which is the body trying to repair the damage?

It's an attempt at repair, yes.

But this repair mechanism driven by PDGF actually ends up thickening the vessel wall and making the underlying atherosclerosis worse.

A tragic positive feedback loop?

It is.

The very process of repair contributes to the chronic disease.

Now, we often hear about the intrinsic pathway factors, 12, 11, 9, 8, mostly in the context of lab tests like the APTT.

Does it play a real role in a clot forming inside the body?

It does, especially in pathological arterial thrombosis.

While tissue factor and the extrinsic pathway are the primary initiators,

the intrinsic pathway is definitely involved in vivo.

How so?

It's involved through contact activation.

Think of that damaged non -endothelial surface of the ruptured plaque.

It provides the perfect surface to activate the contact factors, like factor 12, which then amplifies and propagates the clotting signal.

It helps make sure enough fibrin is generated to really stabilize that platelet -rich clot.

So once that arterial thrombus is formed, what are the immediate dangers for the patient?

Two major acute threats.

The first is just local blockage.

The thrombus gets big enough to completely occlude the vessel right where it formed.

Immediate ischemia.

Right.

And the second, which is often just as dangerous, is embolization.

Pieces breaking off.

Exactly.

Small pieces of the thrombus, usually platelet aggregates and fibrin, break away and travel downstream.

And because arteries get smaller and smaller, they'll eventually get stuck somewhere else.

Precisely.

A classic example is a thrombus in the carotid artery in the neck.

A piece can break off, travel to the brain, and cause a stroke or a TIA, a transient ischemic attack.

And the same can happen from the heart.

Absolutely.

Thromby on a diseased heart valve or inside a heart chamber, especially with atrial fibrillation, can create systemic emboli that travel anywhere.

The brain, the kidneys, the legs,

causing infarcts.

The book describes a really classic arteriogram in Figure 27 .1.

Could you describe that image?

It's quite stark.

It is.

It's a powerful illustration of massive obstruction.

The arteriogram shows the very bottom of the aorta where it splits to go to the legs.

And you can clearly see what's called the saddle embolus.

A saddle?

Yes, because it's sitting right on the bifurcation, straddling the division into the two common iliac arteries, blocking flow to both legs.

And if that wasn't bad enough, there's another separate embolus further down in the left common iliac artery.

It just shows you the sheer scale of tissue that's suddenly at risk.

Which makes identifying the clinical risk factors so critical.

And it's no surprise that they are all tied to the underlying cause, atherosclerosis.

Right, this list is a core of cardiovascular risk assessment.

A positive family history, being male,

hyperlipidemia, so high cholesterol or triglycerides, hypertension, diabetes.

Gout, polycythemia, and of course smoking.

Cigarette smoking, absolutely.

Even certain abnormalities on an ECG can be a flag for underlying arterial damage.

And these aren't just academic points.

Clinicians use these every day to build risk profiles.

They do.

Epidemiological studies take these factors, gender, age, cholesterol, and use them to construct these quantitative risk scores.

They're invaluable for assessing someone before they have an event.

So you can intervene with lifestyle changes or medication?

Exactly, you can counsel them.

Or maybe start a statin or an antiplatelet agent, and hopefully prevent that heart attack or stroke from ever happening.

There are also some emerging risk factors, which seem to tie back to that inflammation thread we started with.

Yes, these are markers that suggest ongoing vascular damage or inflammation.

Things like elevated C -reactive protein, or CRP, high in Leukin -6, elevated fibrinogen.

They all suggest a system that's primed for both vessel damage and clotting.

And finally, there are some systemic diseases that really ramp up the arterial risk.

Definitely.

Cancer is a major one.

We often see a spike in arterial clots in the months before cancer is even diagnosed.

That's fascinating.

It is.

Other conditions include the presence of a lupus anticoagulant, which we'll get into detail on later collagen vascular diseases, a sense disease.

In pretty much all these cases, the underlying mechanism involves inflammation and endothelial damage.

Okay, let's pivot now.

Let's walk across the circulatory system into the veins.

The focus here shifts dramatically, doesn't it?

Away from plaque rupture and towards, well, how the blood is flowing and what's in it.

That shift is absolutely fundamental.

Arterial thrombosis is often a catastrophic failure at one specific damage site.

Venous thrombosis is more of a system management failure.

And to understand that, we have to talk about Virchow's triad.

The cornerstone developed over 150 years ago, but still completely relevant.

To get a venous thrombus, you generally need a combination of three things.

Okay, what are they?

One,

a slowing down of blood flow.

We call that spasis.

Stasis, got it.

Two, hypercoagulability of the blood.

The blood itself is more prone to clotting.

And three.

And three is vessel wall damage.

But, and this is the critical distinction for veins, the first two, stasis and hypercoagulability are by far the most important drivers.

So vessel wall damage is less of a trigger here than it is in arteries?

Much less crucial.

It still plays a role, of course, in things like sepsis, or if there's an indwelling central line or trauma.

But for most DVTs, it's about the flow and the blood itself.

I want to spend a moment on stasis.

Why is slow flow so dangerous in the low -crusher venous system?

Think about the physics of it.

When blood is moving quickly, any activated clotting factors that might pop up are just washed away.

They get diluted and inactivated by the body's natural inhibitors.

So the cascade can't get going.

It can't complete.

But when flow slows down,

especially in places like the valve pockets in the leg veins.

Where deep vein thrombosis often starts.

Exactly.

In those little pockets of stagnant blood, the activated clotting factors can accumulate.

They reach a critical local concentration, and that allows the whole cascade to fire up, generate a ton of thrombin, and form a stable, fibrin -rich clot.

Which explains why immobility is such a potent risk factor.

The single biggest one.

Okay, that makes perfect sense.

Now let's get into the genetics.

This is where it gets really interesting with the hereditary thrombophilias.

And the book points out something surprising.

That inherited clotting disorders are actually more common than inherited bleeding disorders.

It is surprisingly common, yes.

A significant chunk of the population carries one of these traits.

But, and this is important, a VTE rarely happens just because of a genetic factor alone.

It's almost always a classic gene -environment interaction.

So the gene is the loaded gun, and the environment pulls the trigger.

Perfect analogy.

The inherited defect creates a low -level, chronic, hypercoagulable state.

Then an acute trigger, like a major surgery, or pregnancy, or starting estrogen therapy, comes along and pushes the system over the edge.

So if these defects are so common, why does the text caution that testing for them has, and I'm quoting, limited clinical utility?

That's the critical nuance.

For a patient who's just had their first DVT, finding out they have, say, Factor V.

Leiden, doesn't usually change the immediate management.

Which is anticoagulation.

Which is almost always anticoagulation.

And surprisingly, having that genetic marker doesn't necessarily predict a much higher risk of recurrence, compared to someone who had an unprovoked clot for no known reason.

So why do we test it all?

We test because it helps guide the duration of anticoagulation.

Especially after an unprovoked clot, if someone has an unprovoked event and a high -risk genetic factor, you're much more likely to recommend lifelong anticoagulation.

And for family counseling.

And absolutely for family counseling.

Advising relatives about their risks before they face a high -risk situation themselves.

Let's start with the undisputed champion of inherited thrombophilia.

The Factor V.

Leiden mutation.

FEL is the big one.

It's found in an astonishing 3 -7 % of Factor V alleles in white populations.

It's so common we call it polymorphism, not a rare mutation.

We need to nail down the mechanism.

It's a single amino acid change that basically breaks the system's natural break.

That's right.

So normally, activated protein C, APC, acts as a potent anticoagulant.

Its job is to find activated Factor V and cleave it at three specific sites, shutting it down.

Putting the brakes on coagulation.

Exactly.

The FEL mutation is a single nucleotide change that swaps one amino acid for another arginine for glutamine at position 506.

And that position is one of the cleavage sites?

It's the most important one.

By changing that amino acid, the structure of the cleavage site is altered.

APC can no longer recognize it effectively.

It's like changing the locks so the key no longer fits.

So Factor V just keeps on going.

It stays active for much, much longer, leading to a massive acceleration in thrombin generation.

And this phenotype, this effect, is called activated protein C resistance.

Yes.

In the lab, if you add APC to a patient's plasma, their clotting time, the APTT, doesn't prolong as much as it should.

The brake isn't working.

What's the risk profile here?

The difference between having one copy of the gene versus two?

It's substantial.

Heterozygous carriers with one copy have about a five to eight -fold increased risk of a venous clot.

But for the rare people who are homozygous with two copies, the risk just skyrockets to a 30 to 140 -fold increased risk.

Which explains why it's found in up to 40 % of patients who present with a DVT.

It does.

And we have to reinforce this.

What's the management caveat?

If you're a carrier but you've never had a clot.

You are absolutely not automatically put on lifelong anticoagulation.

The absolute risk is still very low.

Very low without other risk factors.

We manage the risk contextually.

We give prophylaxis during high -risk times like surgery or pregnancy.

But we don't treat the gene itself.

Okay, let's quickly run through the other key inherited deficiencies.

Anti -thrombin deficiency.

This is an autosomal dominant condition.

Antithrombin is vital because it neutralizes thrombin and factors out.

So a deficiency leads to recurrent venous thrombi and sometimes arterial ones too.

How do we treat these patients?

The treatment for an acute DVT or PE is the same heparin LMWH.

But for very high -risk situations, we can actually give them antithrombin concentrates to boost their levels temporarily.

Next up, the pair.

Protein C and protein S deficiencies.

Also autosomal dominant.

And they share a really dramatic and scary clinical feature.

They do.

Besides the risk of VTE, they have a tendency to cause skin necrosis if you treat them with warfarin alone.

Warfarin -induced skin necrosis.

Explain that, Megan.

So warfarin works by blocking the production of vitamin K -dependent factors.

That includes the pro -clotting factors, two, seven, nine, and ten.

But it also includes the anti -clotting proteins, C and S.

Protein C has the shortest half -life of all of them, only about eight hours.

So when you start warfarin, the level of protein C plummets first before the clotting factors have had a chance to drop.

So for a short period, you're actually in a hypercoagulable state.

An extreme transient hypercoagulable state.

And if the patient is already deficient, this can cause tiny clots to form in the microvasculature of the skin, leading to necrosis.

It's why we always bridge with heparin when starting warfarin in these patients.

And there's a severe form in infants.

Very rarely.

A homozygous infant presents at birth with catastrophic disseminated intravascular coagulation, or DIC, called purpura fulminans.

It's a devastating condition.

And protein S is just the partner protein for C.

Yes, it's a necessary cofactor for protein C to work.

So a deficiency has a very similar effect.

Okay, moving on to the prothrombin allele G20 2010A.

This one is different.

It's about making too much, not a faulty product.

Correct.

This is a mutation in the promoter region of the prothrombin gene.

It has a prevalence of 2 -3 % and increases thrombosis risk up to fivefold.

And the mechanism is just chronically elevated plasma levels of prothrombin.

How does the promoter mutation do that?

The thinking is that it increases the stability of the pre -messenger RNA.

So the gene isn't necessarily being transcribed more, but the RNA copy sticks around for longer before being degraded.

Which means more protein gets made from each copy.

Exactly, leading to constitutively higher levels of the main precursor to thrombin.

Now, we need to clarify the role of homocysteine.

Its significance has been, well, it's been reevaluated.

This is really important clarification.

High homocysteine can be genetic or acquired, often from B6 or Foley deficiency.

And it was initially strongly linked to thrombosis risk.

But the large trials told a different story.

They did.

For the vast majority of people with moderately high homocysteine, it seems to be unrelated to their risk of venous thrombosis.

The one major exception is in the very rare severe genetic disorder, classic homocysteineuria.

Where the levels are astronomically high.

Five times higher than normal.

And in those patients, thrombosis is a major life -threatening feature.

But for your average patient with a moderately high level, it's not a strong VTE risk factor.

And what about arterial events?

Does lowering the homocysteine with B vitamins help?

So even though high homocysteine is associated with arterial damage, the big intervention trial showed that giving high doses of B6 and folic acid, which does effectively lower the levels.

Did not decrease the risk of recurrent arterial events.

Correct.

Which suggests homocysteine might just be a marker of underlying damage, rather than a direct reversible cause.

The role remains unclear.

And to round this section out, what about fibrinogen defects and ABO blood group?

Fibrinogen defects usually cause bleeding.

But thrombosis is a rare association specifically with congenital dysfibrinogenemia.

That's where the structure of the fibrinogen is abnormal.

And the blood group link.

It's an old but true observation.

People with non -O blood groups, so A, B, or AB, have a statistically higher risk of VTE.

Why is that?

It seems to be because non -O individuals naturally have higher plasma levels of von Willebrand factor and factor VIII, tipping their baseline balance slightly towards clotting.

Okay, let's move into the acquired risk factors.

These are the things that interact with that genetic baseline and really flip the switch.

These are often the most clinically actionable targets.

They can cause a clot, even in someone with no genetic predisposition, but they're far more potent when they're layered on top of something like FEL.

And the single biggest problem in our health systems is hospital acquired thrombosis, or HAT.

HAT is a massive public health issue.

It's responsible for up to half of all VTE cases.

And it's defined as a VTE that occurs within 90 days of a hospitalization.

So the risk extends long after the patient goes home.

Far beyond the hospital doors, which is why there are national strategies mandating risk assessment for every single patient admitted to hospital.

And then prophylaxis for those at high risk.

Absolutely.

Either mechanical, with compression stockings, or pharmacological, with low molecular weight heparin.

And that prophylaxis is often extended after discharge for really high risk surgeries, like hip and knee replacements.

So what are some of those key acquired conditions?

Post -operative risk is huge, especially in the elderly obese patients, or after major abdominal or orthopedic surgery.

Then there's general stasis from immobility, congestive heart failure, a recent heart attack.

Even long airplane flights.

Journeys over four hours, yes.

And a big one is atrial fibrillation, where blood pools in the left atrial appendage, forming clots that can then travel to the brain.

The link with malignancy is also incredibly strong.

A classic perineoplastic syndrome.

The risk goes up with all cancers, but it's particularly high with cancers of the ovary, brain, and pancreas.

What's the mechanism?

Tumors can produce tissue factor themselves.

They can secrete things that directly activate the clotting cascade.

Or a large tumor can just physically compress a vein causing stasis.

And there's a specific red flag for clots in unusual places.

Yes, if a patient presents with a clot in, say, the hepatic vein, Bud Schiari syndrome, or the portal vein, you must have a high suspicion for an underlying myeloproliferative disease, or MPD.

And you'd test for the JAK2V617F mutation?

Exactly.

It could be the first sign of a condition like polycythemia vera.

We keep coming back to inflammation.

It's the great destabilizer.

Inflammatory bowel disease, besetz, lupus, diabetes, they all increase thrombosis risk by upsetting that delicate pro - and anti -coagulant balance.

And other blood disorders.

High risk in conditions with high viscosity, like polycythemia vera.

High risk with high platelet counts in essential thrombocytemia.

And a very high incidence in paroxysmal nocturnal hemoglobinuria, PNH, and sickle cell disease.

Okay, estrogen therapy.

This is a big one.

A very big one.

High dose estrogen dramatically increases thrombotic risk.

Wow.

It's a multi -pronged attack.

And it increases the plasma levels of a whole host of pro -coagulant factors.

Pro -thrombin factor 7, 8, 9, and 10.

So it's boosting the system.

Does it also hit the brakes?

It does.

At the same time, it depresses the levels of the natural anticoagulants, protein S and C.

So you're adding fuel and cutting the brake line simultaneously.

Which explains why the risk is so dose dependent.

Exactly.

The risk is much, much less with modern low dose oral contraceptives and HRT.

But the underlying mechanism is still there.

Now we need to dedicate some serious time to the antiphospholipid syndrome, APS.

This is a really specific condition and it's defined by a deep paradox.

It is.

APS is defined by a clinical event,

a clot or recurrent miscarriage, plus the lab finding of persistent antiphospholipid antibodies.

And the diagnostic challenge centers on the lupus anticoagulant or LA.

Okay, explain the paradox of the lupus anticoagulant.

So in the lab, this antibody interferes with phospholipid dependent clotting tests.

It makes the APTT prolonged.

Which looks like a bleeding tendency, hence the name anticoagulant.

Exactly.

And crucially, if you mix the patient's plasma 50 .50 with normal plasma, the APTT does not correct, which tells you there's an inhibitor present.

So the lab test says bleeding.

But the clinical reality is strong,

recurrent thrombosis in the patient.

The great paradox.

It is.

We think these antibodies, which target phospholipid binding proteins, somehow disrupt the regulation of clotting on cell surfaces, leading to a prothrombotic state.

How do you confirm the diagnosis?

It sounds complex.

It requires a multi -faceted approach.

You confirm the LA with a second specific test, like the Dilute -Russell's vipervenom test.

Then you also run immunoassays for specific antibodies,

like anti -cardiolipin and anti -beta 2 -glycoprotein I.

And the clinical criteria are just as important.

The antibody alone is not enough.

That's vital.

To make the diagnosis, the lab tests have to be persistently positive, at least 12 weeks apart.

And the patient must have had a definite clinical event.

Why the persistence?

Because up to 5 % of healthy people can have a transient antibody, usually after an infection, that has no clinical significance at all.

And the clinical manifestations are broad.

Very.

Arterial events like stroke or MI, venous events like DVT or PE, recurrent fetal loss due to placental clots,

thrombocytopenia, and a skin sign called levido reticularis.

And the treatment is long -term anticoagulation.

Typically long -term warfarin, aiming for an INR of 2 .0 to 3 .0, sometimes higher for recurrent events.

Okay, let's move into our final sections on investigation and diagnosis.

How does a clinician decide when to order a full thrombophilia panel?

It's a strategic decision.

As we said, it rarely changes the immediate management of a first clot.

Its main role is to influence the decision for extended anticoagulation, especially after an unprovoked event, and to help with family counseling.

So let's run down that lab panel.

What are the key tests?

You always start broad.

A full blood count and blood film to look for an underlying MPD or signs of malignancy.

Then the basic coagulation screen.

PT and APTT.

A short APTT can suggest activated factors.

A prolonged uncorrected APTT screams lupus anticoagulant.

And the specific assays.

For APS, the anti -cardiolipin and anti -beta 2 -GPI antibodies.

For the hereditary defects, we do functional assays for antithrombin, protein C, and protein S activity.

And now we can do genetic tests?

Yes.

DNA analysis to confirm factor V Leighton and the prothrombin G202210A variant is standard.

And then specialized tests like flow cytometry for PNH or the JAK2 mutation test if the clot is in an unusual site.

Okay, let's get clinical.

Diagnosing a deep vein thrombosis.

What are the signs?

You suspect it in anyone with an acutely painful swollen limb,

unilateral calf or thigh swelling, pitting edema, tenderness.

And we should stress, the classic Holman sign is completely unreliable.

And to structure that suspicion, clinicians use the Wells score.

The Wells score is a brilliant triage tool.

It assigns points for risk factors like active cancer, recent surgery or immobility, and clinical signs like calf swelling or tenderness.

And you subtract points if another diagnosis seems more likely.

Yes, you subtract two points if you think it's probably cellulitis or a muscle tear.

A score of zero or one is low probability.

Two or more is high probability.

And that score dictates what you do next.

Specifically, how you use the D -dimer test.

D -dimer measures fiber and breakdown products.

Its real power is its high negative predictive value.

Meaning if it's negative, you can be very confident there's no clot.

Exactly.

A negative D -dimer in a patient with a low Wells score reliably excludes a DVT or PE.

It's an incredible tool that lets us avoid unnecessary imaging in a huge number of patients.

But it has limitations.

Big ones.

It's not specific.

It's elevated in surgery, trauma, cancer, pregnancy, inflammation.

In those situations, a positive result is meaningless.

And you have to go straight to imaging.

And for DVT imaging, the first line method is compression ultrasound.

Yes, it's not invasive and highly reliable.

The principle is simple.

A normal vein is like a soft tube.

It collapses when you press on it with the probe.

A thrombo's vein is filled with solid clot.

It's rigid and does not collapse.

And you can add color Doppler to see the blood flow.

Right.

You'd see no flow or reduced flow within that non -compressible vein.

What about the old gold standard contrast phonography?

It's now largely obsolete.

It's invasive, painful, uses radiation and contrast dye, and can even cause a DVT itself.

It's only used in very complex cases now.

Okay, let's move quickly to diagnosing a pulmonary embolus or PE, the clinical feature.

Sudden shortness of breath, sharp pleuritic chest pain, a rapid heart rate, a cough.

You have to suspect it immediately in anyone with risk factors like recent surgery or a known DVT.

What are the first tests?

A chest x -ray, which is often surprisingly normal, and NECG, which can show signs of right heart strain if the PE is massive.

And D -dimer plays the same exclusion role here?

Yes.

In a low -probability patient, a negative D -dimer rules out PE.

For definitive imaging, what's the standard?

The standard first -line test now is

How does that visualize the clot?

It uses a spiral CT scanner timed perfectly with an injection of IV contrast dye.

The contrast lights up the pulmonary arteries, and the clot appears as a dark filling defect where the contrast can't flow.

The images are incredibly clear and definitive.

All right, we conclude our deep dive with the long -term complication of DVT, post -thrombotic syndrome, or PTS.

This is a major source of chronic pain and disability.

It can occur in up to a third of patients after a lower -lin DVT.

What's the mechanism?

How does the old clot cause new problems years later?

When that initial thrombus organizes and recanalizes, it often destroys the delicate one -way valves inside the vein.

The valves that stop blood from flowing backwards?

Exactly.

Without those valves, you get chronic venous reflux and venous hypertension in the lower leg.

The high pressure forces fluid and blood products out into the surrounding tissues.

And what makes someone more likely to get PTS?

Inadequate anticoagulation in the acute phase, having another clot in the same leg, and if the vein never fully opens up again after the first clot.

What does it look like and feel like for the patient?

The symptoms are chronic pain, heaviness, cramps, itching, all worse at the end of the day.

And the signs are visible.

Skin changes, redness, hardening of the tissue, a brown hyperpigmentation from iron deposits, and in severe cases, painful venous ulcers around the ankle.

And how do we manage it?

Management is really about symptom control.

Compression stockings can help with the discomfort and swelling.

Early walking after a DVT might reduce the incidence.

And while anticoagulation doesn't treat PTS, it might be needed long term to prevent another clot in that already damaged leg.

So to just quickly recap this whole deep dive, thrombosis is all about pathological plugs of platelets and fibrin.

And we have to think about it in two distinct ways.

Arterial thrombosis, which is driven by vessel wall injury atherosclerosis and requires us to think about lifestyle, antiplatelet drugs, and mechanical risk factors.

And then venous thrombosis, which is a problem of flow and blood composition.

There, you have to remember, virtuos triad stasis and hypercoagulability are king.

And diagnosis hinges on that smart combination of clinical risk scoring, like the Wells score, with D -dimer for exclusion and non -invasive imaging like ultrasound and CTPA for confirmation.

And remember the major players in hypercoagulability, the common genetic ones like Factor V.

Leiden and the acquired risks like malignancy and the paradoxical antiphospholipid syndrome.

It's all about that fragile balance.

And as we close, here is a final provocative thought for you to chew on.

Considering the extremely high prevalence of Factor V.

Leiden in some populations up to 7 % and that it has a known side effect of a slightly reduced bleeding tendency.

What non -thrombotic evolutionary advantage might have selected for this mutation to be maintained for thousands of years?

Was it about surviving childbirth?

Or maybe surviving traumatic injury in a world without hospitals?

A fascinating question about evolutionary trade -offs.

Absolutely.

Thank you for diving deep with us today.